BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. is a global biotechnology company based in San Rafael, California. Founded in March 1997, it specializes in developing and commercializing therapies for rare genetic diseases. With a workforce of 3,401 employees and reported revenue of $2.419 billion in 2023, BioMarin has established a strong presence in the rare disease therapeutics market. The company focuses on enzyme replacement therapies and genetic medicine innovation, targeting conditions with significant unmet medical needs. Its key products include Aldurazyme® for mucopolysaccharidosis type I, Naglazyme® for MPS VI, Palynziq® for phenylketonuria, and Roctavian® for severe hemophilia A, among others. BioMarin also maintains a robust pipeline aimed at conditions like Duchenne muscular dystrophy and emphasizes gene therapy and precision medicine in its research and development efforts. With manufacturing facilities in California and Ireland, BioMarin ensures a resilient global supply chain to support its operations.